Skip to main navigation

Stoke Therapeutics

Join Our Team
Contact Us

About Us
Our Story
Our Science
Our Work in Dravet
Our Pipeline
Investors & Media

Press Releases

Press Releases

For media inquiries, please contact:

Dawn Kalmar
Chief Communications Officer
781-303-8302
dkalmar@stoketherapeutics.com

Year

May 18, 2021

Stoke Therapeutics to Present at the UBS Global Healthcare Virtual Conference

May 10, 2021

Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates

May 4, 2021

Stoke Therapeutics Presents New Data That Demonstrate Tango Antisense Oligonucleotides (ASOs) Increase OPA1 Protein Production and Improve Mitochondrial Function in Cells Derived From Patients With Autosomal Dominant Optic Atrophy (ADOA)

March 30, 2021

Stoke Therapeutics Announces MHRA Authorization to Initiate Phase 1/2a Clinical Trial of STK-001 for Dravet Syndrome in the United Kingdom

March 24, 2021

Stoke Therapeutics to Present at Upcoming Investor Conferences

March 9, 2021

Stoke Therapeutics Reports Full Year 2020 Financial Results and Provides Business Updates

March 4, 2021

Stoke Therapeutics to Present at the Barclays Global Healthcare Conference

January 4, 2021

Stoke Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

Toolkit

Email Alerts

Contact IR

FAQ

© 2021 Stoke Therapeutics,
all rights reserved.

Terms of Use
Privacy Policy

Home
About Us
- Leadership
- Board of Directors
- Scientific Advisory Board
- COVID-19 Statement
- Racial Equity
Our Story
Our Science
Our Work in Dravet
Our Pipeline
Investors & Media
- Overview
- Media Room
- Press Releases
- Events & Presentations
- Financials & SEC Filings
- Stock Information
- Analyst Coverage
- Governance
Join Our Team
Contact Us